Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.4.47 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Jiemei Shi and 7 co-authors. Institution: Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China. Major MEDLINE topics: Recombinant Fusion Proteins, Genetic Therapy, Receptors, Vascular Endothelial Growth Factor, Dependovirus. 51 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
To evaluate the safety and efficacy of a novel gene therapy vector, covalently closed-end double-stranded adeno-associated virus-aflibercept-Fc-YTE (cceAAV-aflibercept-Fc-YTE; clinical trial name F-CRG-B191), designed for sustained anti-vascular endothelial growth factor (VEGF) expression in the treatment of neovascular age-related macular degeneration (nAMD).
Methods
We developed cceAAV-aflibercept-Fc-YTE. The therapeutic efficacy of cceAAV-aflibercept-Fc-YTE was evaluated in both mice and non-human primate (NHP) models with laser-induced choroidal neovascularization (CNV). The incidence of grade IV CNV lesions was quantified. A first-in-human administration of F-CRG-B191 was conducted to assess anatomical and functional outcomes, as well as safety. Immune responses and retinal toxicity were monitored in NHPs and the patient post-injection.
Results
Compared to conventional AAV vectors expressing aflibercept, cceAAV-aflibercept-Fc-YTE significantly reduced the incidence of grade IV CNV lesions in both mice and NHP models. In the human subject, F-CRG-B191 administration led to a sustained reduction in CNV area and improvement in visual acuity. No significant immune response or retinal toxicity was observed in either preclinical models or the treated patient. Conclusions: cceAAV-aflibercept-Fc-YTE (F-CRG-B191) is a promising gene therapy candidate for nAMD, demonstrating potent anti-VEGF efficacy, durable therapeutic effects, and favorable safety profiles in both preclinical and early clinical settings.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Myopia and Related Eye Diseases, NHC, Shanghai, China.
- Shanghai Correge Pharmaceutical Technology Co., Ltd., Shanghai, China.
Cite
APA
Shi, J., Xu, H., Zhao, H., Zhao, J., Chen, L., Xu, P., Jia, D., & Jiang, C. (2026). Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.4.47
Vancouver
Shi J, Xu H, Zhao H, Zhao J, Chen L, Xu P, et al. Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.4.47
BibTeX
@article{Shi2026,
author = {Shi, Jiemei and Xu, Huan and Zhao, Hongmei and Zhao, Jiajie and Chen, Lihui and Xu, Ping and Jia, Dan and Jiang, Chunhui},
title = {Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.4.47}
}
EUVIMED